Loading...
By Kelly Young
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
Low- or medium-risk monoclonal gammopathy of undetermined significance (MGUS) can progress to multiple myeloma within 5 years, according to a study in JAMA Oncology.
Researchers studied a group of nearly 700 people aged 55 to 74 who were diagnosed with progressing or stable MGUS. Of these, 159 who progressed to multiple myeloma during the study were matched to patients with MGUS who didn't progress.
Among those with available serum samples, roughly 53% of those who progressed to multiple myeloma previously had MGUS with a high risk score. Of these, 70% had converted from low- or intermediate-risk MGUS to multiple myeloma within 5 years. Patients with light-chain MGUS had similar results. Evolving monoclonal proteins, serum-free light chains, and immunosuppression were all associated with progression of disease.
The authors conclude: "The findings of evolving risk patterns support annual blood testing and risk assessment for patients with MGUS or light-chain MGUS."
Comment
LINK(S):
JAMA Oncology article (Free abstract)
JAMA Oncology comment (Subscription required)
Background: NEJM Journal Watch Oncology and Hematology coverage of prognosis of MGUS (Your NEJM Journal Watch registration required)